ADC dealmaking is red hot. Is it sustainable?
The frenzied dealmaking for antibody-drug conjugates is far from over.
In the past 10 days, there’s been a slew of ADC deals. Genmab made its first-ever acquisition — of ProfoundBio, which is in the clinic with multiple ADCs. Merck made a small bet on a startup looking to make the drugs safer on the heels of a massive ADC deal in the fall. Ipsen acquired an asset on the verge of entering human studies, and blue-chip investors doled out $158 million for an ADC startup on the brink of Phase 3.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
